Literature DB >> 18202975

Characterization of mesenchymal stromal cells derived from full-term umbilical cord blood.

M F Manca1, I Zwart, J Beo, R Palasingham, L-S Jen, R Navarrete, J Girdlestone, C V Navarrete.   

Abstract

BACKGROUND: Multipotent mesenchymal stromal cells (MSC) are of interest for their potential to repair bone and cartilage, and also their immunosuppressive properties. Umbilical cord blood (UCB) is reported to contain MSC, and therefore may be a useful source of these cells for clinical applications.
METHODS: We evaluated protocols for isolating MSC from UCB and characterized the surface phenotype, differentiation potential and immunoregulatory properties of the cells obtained.
RESULTS: Ten of 25 UCB units processed yielded MSC-like colonies, with depletion of lineage+ cells providing a higher efficiency. Only two of the cultures could be expanded satisfactorily; the remainder failed to proliferate. One culture generated transformed lines that were grossly aneuploid, had up-regulated TERT transcripts and had lost CD90 expression and the capacity to differentiate. The two propagated UCB-MSC lines were similar to those from bone marrow but were not identical to each other, with differences seen in expression of surface markers and cytoskeletal proteins. Both underwent osteogenesis, but at different rates and to different degrees, while neither generated adipocytes. When added as a third party to a mixed lymphocyte culture, both suppressed proliferation. DISCUSSION: MSC-like cells can be isolated from UCB, but at low efficiencies, and they exhibit a variety of morphologies, growth rates and differentiation potentials and can transform in culture.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202975     DOI: 10.1080/14653240701732763

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  16 in total

1.  Chondrogenesis from umbilical cord blood cells stimulated with BMP-2 and BMP-6.

Authors:  Cristiane Sampaio de Mara; A S S Duarte; A R Sartori-Cintra; A C M Luzo; S T O Saad; I B Coimbra
Journal:  Rheumatol Int       Date:  2012-01-12       Impact factor: 2.631

Review 2.  Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility.

Authors:  Tokiko Nagamura-Inoue; Haiping He
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 3.  Vascular stem cells-potential for clinical application.

Authors:  Sadie C Slater; Michele Carrabba; Paolo Madeddu
Journal:  Br Med Bull       Date:  2016-06       Impact factor: 4.291

Review 4.  Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials.

Authors:  Ana Maria Blanco Martinez; Camila de Oliveira Goulart; Bruna Dos Santos Ramalho; Júlia Teixeira Oliveira; Fernanda Martins Almeida
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

5.  Migration, proliferation, and differentiation of cord blood mesenchymal stromal cells treated with histone deacetylase inhibitor valproic Acid.

Authors:  Leah A Marquez-Curtis; Yuanyuan Qiu; April Xu; Anna Janowska-Wieczorek
Journal:  Stem Cells Int       Date:  2014-03-16       Impact factor: 5.443

6.  Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis.

Authors:  Kyle D Fink; Julien Rossignol; Andrew T Crane; Kendra K Davis; Matthew C Bombard; Angela M Bavar; Steven Clerc; Steven A Lowrance; Cheng Song; Laurent Lescaudron; Gary L Dunbar
Journal:  Stem Cell Res Ther       Date:  2013-10-24       Impact factor: 6.832

Review 7.  Could cord blood cell therapy reduce preterm brain injury?

Authors:  Jingang Li; Courtney A McDonald; Michael C Fahey; Graham Jenkin; Suzanne L Miller
Journal:  Front Neurol       Date:  2014-10-09       Impact factor: 4.003

8.  Comparative analysis of multilineage properties of mesenchymal stromal cells derived from fetal sources shows an advantage of mesenchymal stromal cells isolated from cord blood in chondrogenic differentiation potential.

Authors:  Alice Pievani; Valeria Scagliotti; Francesca Maria Russo; Isabella Azario; Benedetta Rambaldi; Benedetto Sacchetti; Simona Marzorati; Eugenio Erba; Giovanni Giudici; Mara Riminucci; Andrea Biondi; Patrizia Vergani; Marta Serafini
Journal:  Cytotherapy       Date:  2014-05-01       Impact factor: 5.414

9.  Third party cord blood transplant boosts autologous hematopoiesis in a case of persistent bone marrow aplasia after double transplant failure for B-thalassemia major.

Authors:  Giuseppe Visani; Paola Picardi; Barbara Guiducci; Federica Loscocco; Claudio Giardini; Moira Lucesole; Sara Barulli; Teresa Ricciardi; Alessandro Isidori
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-15       Impact factor: 2.576

10.  Comparative Evaluation of Human Mesenchymal Stem Cells of Fetal (Wharton's Jelly) and Adult (Adipose Tissue) Origin during Prolonged In Vitro Expansion: Considerations for Cytotherapy.

Authors:  I Christodoulou; F N Kolisis; D Papaevangeliou; V Zoumpourlis
Journal:  Stem Cells Int       Date:  2013-03-03       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.